Skandinaviska Enskilda Banken AB publ Acquires 403 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Skandinaviska Enskilda Banken AB publ lifted its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 0.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 150,928 shares of the medical research company’s stock after acquiring an additional 403 shares during the period. Skandinaviska Enskilda Banken AB publ owned approximately 0.08% of IQVIA worth $31,912,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in IQV. Rise Advisors LLC bought a new stake in IQVIA in the first quarter valued at $31,000. Versant Capital Management Inc boosted its stake in shares of IQVIA by 733.3% in the 2nd quarter. Versant Capital Management Inc now owns 125 shares of the medical research company’s stock valued at $26,000 after purchasing an additional 110 shares in the last quarter. Riverview Trust Co acquired a new stake in shares of IQVIA during the 1st quarter worth about $32,000. Opal Wealth Advisors LLC bought a new position in IQVIA during the 2nd quarter valued at about $27,000. Finally, International Assets Investment Management LLC acquired a new position in IQVIA in the second quarter valued at about $32,000. Institutional investors own 89.62% of the company’s stock.

Insider Activity at IQVIA

In related news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total transaction of $320,229.00. Following the completion of the transaction, the insider now owns 19,536 shares in the company, valued at $4,812,302.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

A number of research analysts have recently issued reports on IQV shares. Royal Bank of Canada began coverage on shares of IQVIA in a research note on Wednesday, September 4th. They issued an “outperform” rating and a $275.00 target price for the company. JPMorgan Chase & Co. boosted their price objective on IQVIA from $260.00 to $288.00 and gave the stock an “overweight” rating in a research note on Monday, August 5th. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and lowered their target price for the company from $266.00 to $242.00 in a research note on Wednesday, July 24th. Barclays upped their price target on shares of IQVIA from $255.00 to $275.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Finally, Argus upgraded shares of IQVIA to a “strong-buy” rating in a research report on Wednesday, July 31st. Four analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $267.00.

IQVIA Price Performance

IQV opened at $242.24 on Friday. The company has a fifty day moving average price of $240.60 and a two-hundred day moving average price of $234.19. The firm has a market capitalization of $44.16 billion, a PE ratio of 33.09, a P/E/G ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a 52 week low of $167.42 and a 52 week high of $261.73. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85.

IQVIA (NYSE:IQV) last released its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, beating analysts’ consensus estimates of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The business had revenue of $3.81 billion during the quarter, compared to the consensus estimate of $3.79 billion. During the same quarter in the prior year, the company posted $2.22 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. As a group, analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.